FDA Accepts EntreMed's IND Application for Panzem

EntreMed’s investigational new drug application (IND) for Panzem, a treatment for rheumatoid arthritis, has been accepted by the FDA.

In three preclinical models, oral administration of Panzem (2-Methoxyestradiol or 2ME2) demonstrated antiarthritic activity when treatment was started following disease progression.

Panzem also combined well with methotrexate, a current standard of care, resulting in additive antiarthritic activity, EntreMed said.